Advertisement
Singapore markets close in 2 hours 50 minutes
  • Straits Times Index

    3,322.80
    -3.48 (-0.10%)
     
  • Nikkei

    39,701.31
    +528.16 (+1.35%)
     
  • Hang Seng

    18,106.84
    +33.94 (+0.19%)
     
  • FTSE 100

    8,247.79
    -33.76 (-0.41%)
     
  • Bitcoin USD

    61,550.40
    +594.91 (+0.98%)
     
  • CMC Crypto 200

    1,278.98
    -4.80 (-0.37%)
     
  • S&P 500

    5,469.30
    +21.43 (+0.39%)
     
  • Dow

    39,112.16
    -299.05 (-0.76%)
     
  • Nasdaq

    17,717.65
    +220.84 (+1.26%)
     
  • Gold

    2,323.70
    -7.10 (-0.30%)
     
  • Crude Oil

    81.26
    +0.43 (+0.53%)
     
  • 10-Yr Bond

    4.2380
    -0.0100 (-0.24%)
     
  • FTSE Bursa Malaysia

    1,589.82
    +4.44 (+0.28%)
     
  • Jakarta Composite Index

    6,925.67
    +42.96 (+0.62%)
     
  • PSE Index

    6,290.32
    -8.73 (-0.14%)
     

Ardelyx to Participate at the 2024 Jefferies Global Healthcare Conference

Ardelyx, Inc.
Ardelyx, Inc.

WALTHAM, Mass., May 22, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that Michael Raab, President and CEO, and Justin Renz, chief financial and operations officer, will participate in a fireside chat at the 2024 Jefferies Global Healthcare Conference on Wednesday, June 5, 2024 at 10:00 A.M. Eastern Time in New York City.

To access the live webcast of the panel presentation please visit the Events and Presentations page within the Ardelyx website at https://ir.ardelyx.com/events-and-presentations. A replay of the panel presentation will be available on the Ardelyx website for 30 days following the event.

About Ardelyx, Inc.
Ardelyx was founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs. Ardelyx has two commercial products approved in the United States, IBSRELA® (tenapanor) and XPHOZAH® (tenapanor). Ardelyx has agreements for the development and commercialization of tenapanor outside of the U.S. Kyowa Kirin commercializes PHOZEVEL® (tenapanor) for hyperphosphatemia in Japan. A New Drug Application for tenapanor for hyperphosphatemia has been submitted in China with Fosun Pharma. Knight Therapeutics commercializes IBSRELA in Canada. For more information, please visit https://ardelyx.com/ and connect with us on X (formerly known as Twitter), LinkedIn and Facebook.

Investor and Media Contacts:
Caitlin Lowie
clowie@ardelyx.com